Ascendis Pharma ADR (ASND)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2022 | 03-2022 | 12-2021 | 09-2021 | 06-2021 | |
| Sales | 6,556 | 7,662 | 5,759 | 1,313 | 1,231 |
| Cost of Goods | 1,156 | 4,765 | N/A | N/A | N/A |
| Gross Profit | 5,400 | 2,898 | 1,591 | 1,313 | 1,231 |
| Operating Expenses | 156,558 | 147,337 | 133,963 | 115,615 | 142,963 |
| Operating Income | -151,003 | -143,674 | -128,204 | -114,302 | -141,731 |
| Interest Expense | 10,040 | 6,059 | -12,083 | 1,034 | 14,629 |
| Other Income | 74,453 | 9,170 | -5,462 | 20,596 | -5,629 |
| Pre-tax Income | -86,590 | -140,563 | -121,582 | -94,741 | -161,989 |
| Income Tax | -50 | 271 | -116 | -6 | -82 |
| Net Income Continuous | -86,540 | -140,834 | -121,466 | -94,735 | -161,907 |
| Net Income | $-86,540 | $-140,834 | $-121,454 | $-94,746 | $-161,907 |
| EPS Basic Total Ops | -1.55 | -2.48 | -2.13 | -1.73 | -3.01 |
| EPS Basic Continuous Ops | -1.55 | -2.48 | -2.14 | -1.73 | -3.01 |
| EPS Diluted Total Ops | -1.55 | -2.48 | -2.13 | -1.73 | -3.01 |
| EPS Diluted Continuous Ops | -1.55 | -2.48 | -2.14 | -1.73 | -3.01 |
| EBITDA(a) | $-146,586 | $-138,720 | $-123,104 | $-110,030 | $-137,238 |